Medical device company Medical Developments International (ASX:MVP) has successfully raised $20 million from institutional investors as part of their plans to raise a total of $30 million to fund global expansion plans for its flagship non-opioid painkiller, Penthrox (aka the Green Whistle). Capital raised at the Offer Price of $2.00 per share will be used to
Read MoreModern medicine is akin to magic, a notion exemplified when looking at the regenerative power of stem cells. Whilst we’ve barely scraped the surface of what these powerful cells can do, regenerative medicine holds promise as a “magic fix” for many an ailment. Clinical stage regenerative medicine company Regeneus (ASX: RGS) is working to develop
Read More“How much does it hurt, on a scale of 1-10?” Easily the most frustratingly vague of medical questions due to the huge difference in pain thresholds and perceptions. I don’t know about you, but I’m saving my 10 for childbirth. Nonetheless, when the answer falls beneath an epidural-requiring 10, many of us reach for simple
Read MoreWhile prescription opioids have been getting a pretty bad rap over the past few years amid revelations in the US about a certain Sackler family, they still have a vital role to play in healthcare where good guys like Palla Pharma (ASX: PAL) have strengthened their balance sheet with the sale of their manufacturing facility
Read MorePain management is one of the most fascinating arms of medicine. Post-operative pain management, even more so. Practitioners must strike a balance to ensure that acute pain doesn’t turn into chronic pain, and that a patient’s dependence on analgesia is temporary. The many issues with opioid based pain medications are well documented and, with a
Read MoreThe commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug Administration (FDA) raising fresh questions to late-stage drug development company, Paradigm Biopharmaceuticals (ASX: PAR). The FDA response related to Paradigm’s application for Investigational New Drug status to be granted for their focus compound, Pentosan Polysulfate
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.